Who owns Ascendis Pharma (ASND)? Superinvestor holders
2 superinvestors of the 157 tracked here hold Ascendis Pharma (ASND) in their latest 13F filing, with $2.7B between them. Peter Kolchinsky gives it the most weight: 23.8% of the reported portfolio. In their latest reported quarter, Polen Capital team opened a position.
Ron Baron sold out of it in their latest quarter.
Key facts
- Superinvestors holding it
- 2 of 157
- Biggest holder
- Peter Kolchinsky, $2.7B
- Largest weight
- Peter Kolchinsky, 23.8%of their portfolio
- Combined value
- $2.7B
- Bought last quarter
- 1
- Sold last quarter
- 1
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Peter KolchinskyRA Capital Management | 23.8% | $2.7B | 10.28M | — | — | Q2 2026 |
| 2 | Polen Capital teamPolen Capital Management | 0.05% | $5M | 21.86K | New | +21.86K | Q3 2026 |
Sold out last quarter
- Ron Baronwas $400.1K · Q3 2026
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 1 | 21.86K | $5M | 1 | 1 |
| Q2 2026 | 157 | 1 | 10.28M | $2.7B | 0 | 0 |
| Q1 2026 | 157 | 1 | 10.28M | $2.4B | 0 | 3 |
| Q4 2025 | 157 | 3 | 10.41M | $2.2B | 1 | 0 |
| Q3 2025 | 157 | 3 | 10.37M | $2.1B | 0 | 1 |
| Q2 2025 | 157 | 3 | 10.4M | $1.8B | 1 | 2 |
| Q1 2025 | 156 | 6 | 12.23M | $1.9B | 5 | 1 |
| Q4 2024 | 156 | 3 | 10.88M | $1.5B | 2 | 2 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Polen Capital team | 21.86K | — | — | — | — | — | — | — |
| Peter Kolchinsky | · | 10.28M | 10.28M | 10.28M | 10.28M | 10.28M | 10.28M | 10.11M |
| Louis Bacon | — | — | — | 125K | 90K | 120K | 90K | — |
| Andrew Spokes | — | — | — | 1.4K | 1.4K | 1.4K | 1.4K | — |
| Ken Griffin | · | — | — | — | — | — | 1.13M | — |
| Steve Cohen | · | — | — | — | — | — | 569.15K | 503.67K |
| Stanley Druckenmiller | · | — | — | — | — | — | 158.72K | 265.04K |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own ASND?
In their latest 13F filings: Peter Kolchinsky (23.8% of the portfolio, $2.7B), Polen Capital team (0.05% of the portfolio, $5M).
Who bought ASND last quarter?
Polen Capital team (new position). “Last quarter” is each investor's latest reported quarter.
Who sold ASND last quarter?
Sold out entirely: Ron Baron (was $400.1K).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns Ascendis Pharma (ASND)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/ASND/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to ASND by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.